GHRS Share Price Performance
Recent GHRS News & Updates
No updates
GH Research PLC Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.68
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
GH Research PLC Competitors
About GHRS
- Founded
- 2018
- Employees
- 50
- CEO
- WebsiteView website
GH Research PLC, together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States. Its lead product candidate is GH001, an inhalable mebufotenin product candidate, which is in phase 2b clinical trial for treating patients with treatment-resistant depression; and in phase 2a clinical trial for treating bipolar II disorder and a current major depressive episode, as well as female patients with postpartum depression. The company also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
Irish Market Performance
- 7 Days: -4.3%
- 3 Months: 3.7%
- 1 Year: 19.2%
- Year to Date: 14.2%
Over the last 7 days, the market has dropped 4.3%, driven by declines in the Financials and Consumer Staples sectors of 5.4% and 7.9%, respectively. As for the longer term, the market has actually risen by 19% in the last year. As for the next few years, earnings are expected to grow by 8.8% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading